The biotech company reduced full-year guidance and expects so-so third-quarter revenue.
December Nasdaq 100 E-Mini futures (NQZ23) are trending down -0.10% this morning after three major U.S. benchmark indices closed higher on Wednesday as the latest batch of U.S. economic data prompted investors...
MXCT earnings call for the period ending June 30, 2022.
45% Year-Over-Year Core Business Revenue Growth in Second Quarter 2022 Raises 2022 Core Revenue Growth Guidance to Approximately 30% ROCKVILLE, Md.,...
GAITHERSBURG, Md., July 15, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell-engineering company focused on...
GAITHERSBURG, Md., May 13, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell-engineering company focused on...
MXCT earnings call for the period ending March 31, 2022.
MaxCyte Increases 2022 Core Revenue Growth Guidance to be at least 25% and Reiterates Milestone Revenue Guidance of $4 million...
GAITHERSBURG, Md., May 03, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell-engineering company focused on...
GAITHERSBURG, Md., April 20, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell-engineering company focused on...